Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity

Egyptian Rheumatologist

Volumn 37, Issue 1, 2015, Pages 1-6

  Fadda, S ^a   Hamdy, A ^b   Abulkhair, E ^c   Mahmoud Elsify, H ^b   Mostafa, A ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Fayoum University   (Egypt)

^c BENI SUEF UNIVERSITY   (Egypt)

Author keywords

Osteoporosis; Osteoprotegerin; RANKL; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; LEFLUNOMIDE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STEROID;

ADULT; AGE; AGED; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR; FEMUR NECK; FOREARM; GREATER TROCHANTER; HUMAN; LUMBAR SPINE; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SHARP SCORE;

EID: 84924967862     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2014.06.001     Document Type: Review

References (28)

1. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427.
2. Abu-Amer Y., Abbas S., Hirayama T. TNF receptor type I regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem 2004, 93:980-989.
3. Hofbauer L.C., Heufelder A.E. The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001, 44:253-259.
4. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004, 35:1200-1207.
5. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
6. Page G., Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005, 52:2307-2312.
7. Kostenuik P.J., Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001, 7:613-635.
8. Xu S., Wang Y., Lu J., Xu J. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int 2012, 32:3397-3403.
9. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
10. El Meidany Y., El Gaafary M., Ahmed I. Cross-cultural adaptation and validation of an Arabic Health Assessment Questionnaire for use in rheumatoid arthritis patients. Joint Bone Spine 2003, 70:195-202.
11. Aletaha D., Smolen J.S. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI). A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(5 Suppl. 39):S100-S108.
12. Sharp J.T., Young D.Y., Bluhm G.B., Brook A., Brower A.C., Corbett M., et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?. Arthritis Rheum 1985, 28(12):1326-1335.
13. Gough A.K., Lilley J., Eyre S., Holder R.L., Emery P. Generalized bone loss in patients with rheumatoid arthritis. Lancet 1994, 344:23-27.
14. Vega D., Maalouf N.M., Sakhaee K. The role of receptor activator of nuclear factor-kB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92(12):4514-4521.
15. Skoumal M., Kolarz G., Haberhauer G., Woloszczuk W., Hawa G., Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 2005, 26(1):63-69.
16. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44(5):1003-1012.
17. Vanderborght A., Linsen L., Thewissen M., Geusens P., Raus J., Stinissen P. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004, 31(8):1483-1490.
18. Alkady E.A.M., Rashad S.M., Khedr T.M., Mosad E., Abdel-Wahab N. Early predictors of increased bone resorption in juvenile idiopathic arthritis: OPG/RANKL ratio, as a key regulator of bone metabolism. Egypt Rheumatol 2011, 33(4):217-223.
19. Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46(7):1744-1753.
20. Haynes D.R., Crotti T.N., Loric M., Bain G.I., Atkins G.J., Findlay D.M. Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40(6):623-630.
21. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T., Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor jB ligand on adult T-cell leukemia cells. Blood 2002, 99:634-640.
22. Haugeberg G., Conaghan P.G., Quinn M., Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo controlled study. Ann Rheum Dis 2009, 68(12):1898-1901.
23. Çakirca G., Mete N., Batmaz I., Sariyildiz M.A., Mehmet Ali Ulu M.A., Yazmalar L., et al. The relationship between bone mineral density and levels of RANKL, osteoprotegerin and cathepsin-K in patients with rheumatoid arthritis. Dicle Tip Derg 2012, 39(4):479-484.
24. Oelzner P., Franke S., Lehmann G., Eidner T., Müller A., Wolf G., et al. Soluble receptor activator of NF kappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 2007, 26(12):2127-2135.
25. Gheita T., Fawzy S., Rizk A., Hussein H. Impaired bone formation and osteoporosis in postmenopausal elderly onset rheumatoid arthritis patients. Egypt Rheumatol 2011, 33(3):155-162.
26. Wisłowska M., Jakubicz D., Olczyk-Wrochna K. The role of OPG/RANKL/RANK in bone destruction in rheumatoid arthritis. Reumatologia 2009, 47(2):67-74.
27. Geusens P.P., Landewe R.B., Garnero P., Chen D., Dunstan C.R., Lems W.F., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006, 54(6):1772-1777.
28. Ghorbanihaghjo A, Hajialilo M, Shahidi M, khabazi A, Kolahi S, Nakhjavani MRJ et al. Osteoprotegerin (OPG) and matrix Gla protein (MGP) in rheumatoid arthritis patients: Relation to disease activity. Egypt Rheumatol 2014;36(3):111-16.